AbstractFas is a membrane protein belonging to the death receptor family. Cross‐linking of Fas by its ligand, FasL, or agonistic anti‐Fas antibodies, induces apoptosis of cells expressing Fas on the membrane by triggering a cascade of caspases. Since many different tumours express Fas on their membrane, targeting Fas‐mediated apoptosis by anti‐Fas antibodies may be a promising anticancer therapy. Unfortunately, not all Fas‐expressing cells are sensitive to Fas‐mediated apoptosis. This has resulted in the discovery of many different inhibition mechanisms of Fas‐mediated apoptosis. In addition, mutations in the Fas or p53 gene can also influence the sensitivity for Fas‐mediated apoptosis. However, the role of wild‐type p53 in Fas expression is still controversial. Because several different cytotoxic drugs are able to induce Fas membrane expression, combination therapy of anticancer drugs with anti‐Fas antibodies or FasL is conceivable as an anticancer strategy. The efficiency of the induction of Fas‐mediated apoptosis by anti‐Fas antibodies, FasL‐expressing cells or recombinant FasL (rFasL) in tumours has been demonstrated in vivo in solid tumours implanted in mice. Unfortunately, systemic treatment with anti‐Fas antibodies or rFasL causes severe damage to the liver, so most preclinical studies are now focusing on circumvention of this problem by local administration of FasL, or on the use of inducible FasL‐expressing vectors as gene therapy. Copyright © 2001 John Wiley & Sons, Ltd.